Cardiopulmonary bypass in a child with hereditary angioedema

Čače, Neven; Brusich, Sandro; Dessardo, Sandro; Ahel, Jurica

doi:10.1111/j.1442-200x.2005.02032.x

Cited by 3 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No angioedema occurred, irrespective of the duration of the procedure. 71 In five additional case-series studies (n ϭ 10), 30,33,34,36,72 and 21 case reports, 42,44,45,47,58,63,[73][74][75][76][77][78][79][80][81][82][83][84][85][86][87] there were no cases of angioedema after administration of C1-INH as short-term prophylaxis. …”

Section: Preprocedural Short-term Prophylaxis With C1-inhmentioning

confidence: 98%

“…21 The remaining patients received C1-INH before various other (i.e., cardiopulmonary bypass, septal deviation, eye, and abortion) or unspecified surgical interventions. 18,23,24,33,44,71,72,[83][84][85][86] In a retrospective and prospective cohort study, two patients received C1-INH prophylactically 30 minutes before surgery (one dental and multiple abdominal surgeries, respectively), and in both patients there were no HAE-associated complications during or after the surgery. 13 In a retrospective cohort study that evaluated 705 tooth extractions in 171 patients with HAE-C1-INH, the rate of facial swelling and/or life-threatening laryngeal edema was 21.5% for 577 extractions without prophylaxis compared with 12.5% for 138 extractions with prophylaxis.…”

Section: Preprocedural Short-term Prophylaxis With C1-inhmentioning

confidence: 99%

See 1 more Smart Citation

Treatment with C1-esterase inhibitor concentrate in type I or II hereditary angioedema: A systematic literature review

Bork

Steffensen²,

Machnig³

2013

allergy asthma proc

View full text Add to dashboard Cite

Hereditary angioedema (HAE) due to C1 esterase inhibitor (HAE-C1-INH) deficiency is a rare genetic disorder presenting with recurrent episodes of skin swellings, abdominal pain attacks, and potentially fatal laryngeal edema. This study was designed to review the efficacy and safety of pasteurized, human, plasma-derived C1-INH concentrate for the treatment of patients with HAE-C1-INH. A systematic search of electronic databases up to December 2011 was performed without language or date restrictions. Two reviewers completed the study selection using predefined inclusion criteria, tabulated, and analyzed the data. The data were inappropriate for meta-analysis; thus, a qualitative synthesis was performed. We identified 89 studies (≍2000 patients) that investigated C1-INH. Replacement therapy with C1-INH significantly shortened time to onset of symptom relief in HAE attacks compared with placebo in a randomized controlled trial, and similar improvements were consistently reported in observational and descriptive studies, accompanied by improvements in patients' quality of life. C1-INH has been shown to be effective for patients receiving home therapy and short- and long-term prophylaxis. Treatment with C1-INH was generally well tolerated. Administration of C1-INH was not associated with transmission of viruses or development of autoantibodies irrespective of treatment duration. This research provides additional confirmation of the efficacy of C1-INH in the treatment and prevention of HAE attacks. C1-INH is generally safe and well tolerated and has an excellent safety record for over 25 years of clinical use.

show abstract